Our Approach
Braindoot Lifesciences is advancing innovative therapies for CNS malignancies and traumatic brain injury (TBI) through the development of novel small-molecule therapeutics enabled by our proprietary Braindoot Linker System (BLiS) platform. BLiS is designed to selectively deliver therapeutics to the central nervous system, overcoming the blood-brain barrier while minimizing systemic exposure and off-target toxicity. By combining precision brain targeting with innovative therapeutics, we aim to address critical unmet clinical needs and improve outcomes for patients with the most challenging brain diseases.
Our Platforms
BLiS
Novel linker platform to develop a library of tunable linkers. These linkers conjugated to therapeutically active molecules for enhanced therapeutics with higher CNS penetration and Tumor exposure to expand therapeutic utility of drugs.
PRiS
Utilizing AI enables faster identification of potential small-molecule drug candidates for novel targets. Our proprietary platform integrates in vitro, in silico and in vivo data to predict BBB permeability with high specificity and sensitivity.
TRiS
Recapitulates the structural, molecular and functional properties, cellular complexity and transporter regulation of the human blood brain barrier (BBB), enhancing its translational predictability.
We have identified a clinically validated compound targeting a novel pathway in brain cancers. To overcome the challenges of brain delivery, we are developing the BLiS platform that enables efficient transport of the molecule across the blood–brain barrier (BBB). This approach is designed to enhance therapeutic efficacy in brain tumors while minimizing off-target toxicities in peripheral organs.
In parallel, we have developed a proprietary, humanized BBB platform that faithfully mimics the physiological blood–brain barrier using human astrocytes, pericytes, and primary endothelial cells. This platform enables selective and predictive assessment of compound transport into brain and tumor compartments.
Our machine learning–driven discovery engine further strengthens this platform by identifying compounds with high BBB permeability. These predictions allow us to prioritize a focused set of molecules for experimental validation using our human BBB model. Leveraging these insights, we can rationally modify drug candidates to optimize brain delivery and selectively target diseased regions of the brain.